NeuroOne Medical Technologies Corporation

Good day, ladies and gentlemen, and welcome to the NeuroOne Medical Technologies Corporation first quarter of fiscal year 2024 financial results conference call. Today's call will be conducted by the company's chief financial officer, Ron McClurg. Before I turn the call over to Mr. McClurg, I'd like to remind you that this conference call will include forward-looking statements within the meaning of U.S. federal securities laws with respect to future operations, financial results, events, trends, and performance, which are based on management's beliefs and assumptions as of today's call or other specified date. Forward-looking statements may involve known and unknown risks, uncertainties, and other factors, which may cause actual results to differ materially from those expressed or implied by such statements. See NeuroOne's financial results press release and SEC filings for information regarding specific risks and uncertainties that could cause actual results to differ. Except as required by law, NeuroOne undertakes no obligation to update such forward-looking statements. With that, I will turn the call over to Mr. Ron McClurg, CFO of NeuroOne. Please go ahead, sir.

Thank you, operator. Before I begin, I wanted to mention that Dave Rosa, our CEO, had minor surgery, which prevented him from being able to present this afternoon, so I will be handling the call. During the first quarter of fiscal 2024, we continued to make significant progress on our objectives relating to commercialization and product development. First, I would like to remind the audience of our recent milestone achievement of receiving FDA clearance for our 1RF ablation system, the first FDA-cleared system with an intended use for both recording electrical activity and ablation of nervous tissue utilizing the same device. As previously noted, we submitted a 510K application to the FDA in June 2023 for the 1RF ablation system, and we received that 510K clearance from the FDA in December of 2023 for the creation of radio frequency lesions in nervous tissue for functional neurosurgical procedures. We are very excited to be the first to market this novel technology in the United States and are preparing to initiate a limited commercial launch in the second quarter of calendar 2024. We will remain in discussions with potential strategic partners regarding the licensing of the technology for brain ablation procedures. And we expect to reach a decision in the near future regarding our commercialization strategy. We also remain open to commercializing the device directly if we believe it represents the best option for the company. and we are working in parallel on a plan to launch the technology directly. In addition, our team is exploring other applications for the 1RF system to treat pain. We believe that there are additional market opportunities for the 1RF system that we may be able to address, and we will provide further updates in the future. I would now like to provide an update regarding the expanded launch of our EVO-SEG electrode product line. with our commercialization partner, Zimmer Biomed. Zimmer continued to strategically open new centers during our first fiscal quarter. Customer feedback remains positive regarding device performance, and we are seeing usage picking up in recent months. We completed full Salesforce training for Zimmer in January 2024, and we expect to see an increase in Evo SCEG sales and revenue as the launch expands. We believe the launch of the 1RF system will also have a positive impact on customer demand for the Evo SCEG electrode product line. Moving on to our drug delivery program, we have discussed the potential for our SCEG electrode technology to deliver drugs or gene therapies to the brain, as well as record the therapy's impact. During the past quarter, we completed feasibility benchtop testing and an animal study demonstrating the ability to deliver a therapy and provide recording capabilities using the SEG drug delivery system. We are currently in contract discussions with a biotech company regarding their interest in using our device in upcoming clinical studies and have had discussions with other potential partners. We are excited with the prospects of this technology and how it may assist the biopharma industry in their drug or gene therapy delivery development, and also its value clinically in current neurosurgical procedures. If we are able to reach an agreement in our current contract negotiations, the technology has the potential to add revenue later in calendar year 2024. Development efforts with our spinal cord stimulation program to treat chronic back pain continued in our first quarter as members of our physician advisory board successfully placed a nine millimeter paddle electrode utilizing a percutaneous placement approach in a cadaver model. Paddle electrodes are similar in concept to cortical or film electrodes. In addition, we completed a preclinical study of the first acute electrophysiology experiment with Neuro1's lead in a sheep model. Final cord stimulation and pain management remain a priority given the size of the market opportunity and the potential competitive advantages of our technology. I would now like to provide a review of our first quarter fiscal year 2024 financial results. Product revenue was $978,000 in the first quarter of fiscal 2024 compared to product revenue of $115,000 in the first quarter of fiscal 2023. The company had no collaboration revenue in the first quarter of fiscal 24 compared to collaboration revenue of $1,455,000 in the first quarter of fiscal 2023. Collaboration revenue in 2023 was derived from the Zimmer Development Agreement and represents the portion of the exclusivity and milestone fee payments that were eligible for revenue recognition during the period. Total operating expenses in the first quarter of fiscal 2024 were 3.7 million compared to 3.2 million in the first quarter of fiscal 2023. R&D expense in the first quarter of fiscal 2024 was 1.5 million compared with 1.6 million in the same period of fiscal 2023. SG&A expense in the first quarter of fiscal 2024 was 2.2 million compared to 1.7 million in the first quarter of fiscal 2023. The net loss was 3.3 million for the first quarter of fiscal 2024, compared to a net loss of 1.7 million in the first quarter of fiscal 2023. In December of 2023, the company sold common stock under the ATM offering at an average price of $1.45 per share and received net proceeds of 1.2 million. As of December 31, 2023, the company had cash, cash equivalents, and short-term investments of $2.7 million compared to $5.3 million as of September 30, 2023, our previous fiscal year end. The company had working capital of $3.7 million as of December 31, 2023, compared to working capital of $5.5 million as of September 30, 2023. Company had no debt outstanding as of December 31st, 2023. Subsequent to the end of the first quarter in January of 2024, the company sold additional common stock under the ATM offering at an average price of $1.46 per share and received net proceeds of 1.54 million. Operator at this time, I think we can open up for questions.

Absolutely. Thank you. At this time, we will be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. Once again, please press star one if you have a question or comment. The first question comes from Alex Nolik with Craig Hallam. Please proceed.